HRSA HIV/AIDS Bureau Special Sessions
Webinars and other special events by HRSA's HIV/AIDS Bureau.
Resource updated 01/09/2024
Webinars and other special events by HRSA's HIV/AIDS Bureau.
Resource updated 01/09/2024
Blog updated 01/07/2021
Quick reference showing key dates for the EHE Triannual Report and sources of assistance for recipients.
Resource updated 05/13/2024
Instructions on the EHE data collection system.
Resource updated 06/03/2024
Resource updated 03/15/2023
Resource updated 01/05/2024
Event updated 02/21/2023
Blog updated 02/01/2021
Resource updated 01/05/2024
Resource updated 01/05/2024
Resource updated 01/05/2024
Resource updated 09/19/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Rapid has developed into a core feature of the Dorothy Mann Center HIV care continuum, assuring immediate linkage to expert HIV services, immediate initiation of therapy, and rapid viral suppression. Benefits are present for youth prevention services. Rapid access models are feasible and beneficial for youth HIV care and prevention.
Resource (Conference Presentation) updated 09/14/2023
A clinic-based substance abuse screening and treatment program is described. Using the Screening, Brief Intervention, and Referral to Treatment model, this provides annual proactive screening of alcohol/drug use, with a brief provider response and a follow-up motivational interviewing brief intervention, with treatment provided by an embedded provider.
Resource (Conference Presentation) updated 09/14/2023
Oklahoma has been classified by the Department of Health and Human Services as one of the seven states with a high rural HIV burden. Test-and-treat protocols are feasible within high-volume HIV clinics which serve rural and underserved communities to minimize the time to the first appointment to decrease time to viral load suppression.
Resource (Conference Presentation) updated 09/14/2023
This session will focus on key findings and behavioral considerations for long-acting antiretroviral treatment (ART) HIV regimens, given the progress in research, development, and potential approval of these drugs. There will be a brief overview of the ATLAS and FLAIR studies, discussion of the medications, and an outline of the potential impact of the regimens on care delivery models, providers, patients, and payers if they are approved.
Resource (Conference Presentation) updated 09/14/2023